Sutro Biopharma (NASDAQ:STRO) unveiled a series of preclinical successes at the 2026 American Association for Cancer Research (AACR) Annual Meeting, reinforcing its leadership in the design of next-generation antibody-drug conjugates (ADCs).
The data focused on several single- and dual-payload candidates, all of which demonstrated robust antitumor activity across a diverse range of solid tumor models.
The presentation highlighted STRO-004, one of the company's lead candidates, which achieved significant tumor control in preclinical models following a single 5 mg/kg dose.
Critically, the highest non-severely toxic dose (HNSTD) was established at 50 mg/kg, suggesting a wide therapeutic window that could translate to improved safety and efficacy in humans.
Investors are looking toward mid-2026, when the company expects to release initial results from its Phase 1 clinical study of the candidate.
Sutro also shared promising data for STRO-006 and STRO-227, both of which showed dose-dependent antitumor activity.
The company announced that it remains on track to file an Investigational New Drug (IND) application for STRO-227 in late 2026, further expanding its clinical-stage portfolio.
Sutro’s proprietary site-specific conjugation platform is also gaining traction through its high-profile partnerships.
The company noted that ASP2998, a TROP2-targeted immunostimulatory ADC (iADC) developed by partner Astellas Pharma, has already transitioned into clinical dosing.
This milestone underscores the versatility of Sutro's technology in creating complex, dual-action therapies that combine the precision of an antibody with the potency of a payload.